Kwang-hyub C. Han
Expertise in
7
conditions

Kwang-hyub C. Han

Hana Park, 
Songnam, KR 
Expertise in
7
conditions
Hana Park, 
Songnam, KR 

Overview

Kwang-hyub Han practices practicing medicine in Songnam, Republic of Korea.

Mr. Han is highly rated in 7 conditions, according to our data. His clinical expertise encompasses Hepatitis B, Hepatitis, Liver Cancer, Hepatectomy, and Liver Transplant.

He is actively involved in clinical research, co-authoring 359 peer reviewed articles and participating in 3 clinical trials.

Gender

Male

Locations

Hana Park, Songnam, 463712, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase III, Multi-center, Randomized, Double-blinded, Parallel Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues
A Phase III, Multi-center, Randomized, Double-blinded, Parallel Study to Assess the Antiviral Activity and Safety Endpoints for the Treatment of Besifovir 150mg Compared to Tenofovir 300mg in Chronic Hepatitis B Patients Who Have Resistance to Nucleoside Analogues
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Drug
Study Drugs: Besifovir, Tenofovir
Study Phase: Phase 3
Hepatocellular Carcinoma Registry in Asia: The INSIGHT Registry
Hepatocellular Carcinoma Registry in Asia: The INSIGHT Registry
Enrollment Status: Completed
Publish Date: December 05, 2022
A Phase Ⅲ, Multi-center, Randomized, Double-blinded, Parallel Study to Assess the Antiviral Activity and Safety of Besifovir 150 mg Compared to Tenofovir 300 mg in Chronic Hepatitis B Patients for 48 Weeks
A Phase Ⅲ, Multi-center, Randomized, Double-blinded, Parallel Study to Assess the Antiviral Activity and Safety of Besifovir 150 mg Compared to Tenofovir 300 mg in Chronic Hepatitis B Patients for 48 Weeks
Enrollment Status: Unknown
Publish Date: January 27, 2020
Intervention Type: Drug
Study Drugs: Besifovir, Tenofovir
Study Phase: Phase 3
View 2 Less Clinical Trials

359 Total Publications

AI in Oral Health Surveillance: Critical Review.
AI in Oral Health Surveillance: Critical Review.
Journal: Journal of dental research
Published: April 10, 2026

Frequently Asked Questions about Kwang-hyub C. Han

Is Kwang-hyub C. Han a top-rated expert for Hepatitis B?

MediFind is an objective health platform that identifies experts based on real-world data. Kwang-hyub C. Han is classified as an Distinguished expert for Hepatitis B, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Kwang-hyub C. Han participate in research or clinical trials?

Yes. Kwang-hyub C. Han has published 359 articles and abstracts on conditions like Hepatitis B. You can view a list of Kwang-hyub C. Han's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Han's expertise for a condition
ConditionClose
    View All 23 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile